

Dengue Fever - Pipeline Review, H2 2019

<https://marketpublishers.com/r/D0EB571B237EN.html>

Date: December 2019

Pages: 173

Price: US\$ 2,000.00 (Single User License)

ID: D0EB571B237EN

Abstracts

Dengue Fever - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dengue Fever - Pipeline Review, H2 2019, provides an overview of the Dengue Fever (Infectious Disease) pipeline landscape.

Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dengue Fever - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Dengue Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dengue Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 10, 27, 12 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3, 12 and 11 molecules, respectively.

Dengue Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Dengue Fever - Overview

Dengue Fever - Therapeutics Development

Dengue Fever - Therapeutics Assessment

Dengue Fever - Companies Involved in Therapeutics Development

Dengue Fever - Drug Profiles

Dengue Fever - Dormant Projects

Dengue Fever - Discontinued Products

Dengue Fever - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Dengue Fever, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Universities/Institutes, H2 2019

Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Dengue Fever - Pipeline by 60 Degrees Pharmaceuticals LLC, H2 2019

Dengue Fever - Pipeline by Abhelix LLC, H2 2019

Dengue Fever - Pipeline by Abivax SA, H2 2019

Dengue Fever - Pipeline by Aluda Pharmaceuticals Inc, H2 2019

Dengue Fever - Pipeline by Avida Biotech SL, H2 2019

Dengue Fever - Pipeline by Biological Mimetics Inc, H2 2019

Dengue Fever - Pipeline by BioNet- Asia Co Ltd, H2 2019

Dengue Fever - Pipeline by Biotron Ltd, H2 2019

Dengue Fever - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019

Dengue Fever - Pipeline by Cidara Therapeutics Inc, H2 2019

Dengue Fever - Pipeline by Clayton Biotechnologies Inc, H2 2019

Dengue Fever - Pipeline by Codagenix Inc, H2 2019

Dengue Fever - Pipeline by Emergex Vaccines Ltd, H2 2019

Dengue Fever - Pipeline by Ennaid Therapeutics LLC, H2 2019

Dengue Fever - Pipeline by Etna Biotech Srl, H2 2019

Dengue Fever - Pipeline by Excivion Ltd, H2 2019

Dengue Fever - Pipeline by F4 Pharma GmbH, H2 2019

Dengue Fever - Pipeline by GlaxoSmithKline Plc, H2 2019

Dengue Fever - Pipeline by Globavir Biosciences Inc, H2 2019

Dengue Fever - Pipeline by Greffex Inc, H2 2019

Dengue Fever - Pipeline by Hawaii Biotech Inc, H2 2019

Dengue Fever - Pipeline by HSRx Group, H2 2019

Dengue Fever - Pipeline by Humabs BioMed SA, H2 2019
Dengue Fever - Pipeline by Immunomodulation Inc, H2 2019
Dengue Fever - Pipeline by Immunotope Inc, H2 2019
Dengue Fever - Pipeline by Imutex Ltd, H2 2019
Dengue Fever - Pipeline by Indian Immunologicals Ltd, H2 2019
Dengue Fever - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Dengue Fever - Pipeline by ISLA Pharmaceuticals Inc, H2 2019
Dengue Fever - Pipeline by Johnson & Johnson, H2 2019
Dengue Fever - Pipeline by Kineta Inc, H2 2019
Dengue Fever - Pipeline by KM Biologics Co Ltd, H2 2019
Dengue Fever - Pipeline by Macrophage Therapeutics Inc, H2 2019
Dengue Fever - Pipeline by Medigen Inc, H2 2019
Dengue Fever - Pipeline by Najit Technologies Inc, H2 2019
Dengue Fever - Pipeline by Panacea Biotec Ltd, H2 2019
Dengue Fever - Pipeline by Plex Pharmaceuticals Inc, H2 2019
Dengue Fever - Pipeline by ProtInhi BV, H2 2019
Dengue Fever - Pipeline by Riboscience LLC, H2 2019
Dengue Fever - Pipeline by Seagull Labs (I) Pvt Ltd, H2 2019
Dengue Fever - Pipeline by Serum Institute of India Ltd, H2 2019
Dengue Fever - Pipeline by Shionogi & Co Ltd, H2 2019
Dengue Fever - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019
Dengue Fever - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Dengue Fever - Pipeline by TechnoVax Inc, H2 2019
Dengue Fever - Pipeline by Virocovax, H2 2019
Dengue Fever - Pipeline by Visterra Inc, H2 2019
Dengue Fever - Pipeline by VLP Therapeutics LLC, H2 2019
Dengue Fever - Pipeline by Xenothera SAS, H2 2019
Dengue Fever - Dormant Projects, H2 2019
Dengue Fever - Dormant Projects, H2 2019 (Contd..1), H2 2019
Dengue Fever - Dormant Projects, H2 2019 (Contd..2), H2 2019
Dengue Fever - Dormant Projects, H2 2019 (Contd..3), H2 2019
Dengue Fever - Dormant Projects, H2 2019 (Contd..4), H2 2019
Dengue Fever - Dormant Projects, H2 2019 (Contd..5), H2 2019
Dengue Fever - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Dengue Fever, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

60 Degrees Pharmaceuticals LLC
Abhelix LLC
Abivax SA
Aluda Pharmaceuticals Inc
Avida Biotech SL
Biological Mimetics Inc
BioNet- Asia Co Ltd
Biotron Ltd
Chugai Pharmaceutical Co Ltd
Cidara Therapeutics Inc
Clayton Biotechnologies Inc
Codagenix Inc
Emergex Vaccines Ltd
Ennaid Therapeutics LLC
Etna Biotech Srl
Excivion Ltd
F4 Pharma GmbH
GlaxoSmithKline Plc
Globavir Biosciences Inc
Greffex Inc
Hawaii Biotech Inc

HSRx Group
Humabs BioMed SA
Immunomodulation Inc
Immunotope Inc
Imutex Ltd
Indian Immunologicals Ltd
Inovio Pharmaceuticals Inc
ISLA Pharmaceuticals Inc
Johnson & Johnson
Kineta Inc
KM Biologics Co Ltd
Macrophage Therapeutics Inc
Medigen Inc
Najit Technologies Inc
Panacea Biotec Ltd
Plex Pharmaceuticals Inc
ProtInhi BV
Riboscience LLC
Seagull Labs (I) Pvt Ltd
Serum Institute of India Ltd
Shionogi & Co Ltd
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
TechnoVax Inc
Virocovax
Visterra Inc
VLP Therapeutics LLC
Xenothera SAS

I would like to order

Product name: Dengue Fever - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/D0EB571B237EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D0EB571B237EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970